Category Press Releases

Mirum Pharmaceuticals

Mirum Pharmaceuticals Prices $600 Million Convertible Senior Notes Offering, Refinances Portion of 2029 Notes

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes Mirum Pharmaceuticals, Inc. a leading rare disease company, announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior…

Read MoreMirum Pharmaceuticals Prices $600 Million Convertible Senior Notes Offering, Refinances Portion of 2029 Notes
Cellares

Cellares and ProTcell Therapeutics Partner to Automate Manufacturing of ProT-096 Immune Cell Therapy

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence Cellares, the first Integrated Development and Manufacturing Organization and ProTgen, a biotechnology company pioneering targeted Notch activators to reactivate the…

Read MoreCellares and ProTcell Therapeutics Partner to Automate Manufacturing of ProT-096 Immune Cell Therapy
Actio Biosciences

Actio Biosciences Launches KYRON Trial for ABS-1230 in KCNT1 Epilepsy, Joins FDA Rare Disease Program

Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel…

Read MoreActio Biosciences Launches KYRON Trial for ABS-1230 in KCNT1 Epilepsy, Joins FDA Rare Disease Program
Gulf Coast

Phibro Animal Health Corporation Launches Sustainability Platform With VAXA Technologies Partnership

Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership Phibro Animal Health Corporation announced the launch of its new Sustainable Solutions Platform (SSP), a companywide initiative designed to help animal protein,…

Read MorePhibro Animal Health Corporation Launches Sustainability Platform With VAXA Technologies Partnership
Viridian

Viridian Therapeutics Proposes Concurrent Offerings of Notes, Common Stock, and Preferred Stock

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics, Inc. a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and…

Read MoreViridian Therapeutics Proposes Concurrent Offerings of Notes, Common Stock, and Preferred Stock
Travere

Sequenex partners with MedTech Innovator, a leading healthcare startup accelerator

Sequenex Announces Partnership with MedTech Innovator, Industry’s Leading Startup Accelerator Sequenex announced its partnership with MedTech Innovator (MTI), the world’s largest accelerator of medical technology companies. MedTech Innovator matches healthcare industry leaders with innovative early-stage medtech companies for mentorship and…

Read MoreSequenex partners with MedTech Innovator, a leading healthcare startup accelerator
Arrowhead

Arrowhead wins Australian approval for REDEMPLO® (plozasiran) for FCS treatment

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals, Inc. announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine,…

Read MoreArrowhead wins Australian approval for REDEMPLO® (plozasiran) for FCS treatment
Nebius

Nebius to acquire Eigen AI, boosting Nebius Token Factory as a frontier inference platform

Nebius Agrees to Acquire Eigen AI, Strengthening Nebius Token Factory as a Frontier Inference Platform Nebius the AI cloud company, announced an agreement to acquire Eigen AI, a leading inference and model optimization company. The acquisition will strengthen Nebius Token Factory…

Read MoreNebius to acquire Eigen AI, boosting Nebius Token Factory as a frontier inference platform
Compass

Compass Pathways secures FDA rolling NDA review and earns Commissioner’s National Priority Voucher

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner’s National Priority Voucher Compass Pathways plc a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration…

Read MoreCompass Pathways secures FDA rolling NDA review and earns Commissioner’s National Priority Voucher